Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Hendrik-Tobias Arkenau, MD, PhD, FRCP
Executive Medical Director, Drug Development Program; Principal Investigator
Dr. Arkenau joined Sarah Canon in 2000 and serves as medical director of the Drug Development Program, for Sarah Cannon Research Institute, UK. In this role, he leads the UK program development of early clinical and tumor specific trials. He is orchestrates a network of internal and external Principal Investigators and is supports the molecular profiling initiative of Sarah Cannon in collaboration with UCL Advanced Diagnostics.
Arkenau has vast experience in early oncology clinical drug development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before joining Sarah Cannon Research UK, he was senior clinical fellow at the Royal Marsden Hospital and team leader for early drug development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.